B7 homolog 3 in pancreatic cancer
作者机构：Institute of Human GeneticsFaculty of MedicineUniversity of BelgradeBelgrade 11000Serbia Institute of Microbiology and ImmunologyFaculty of MedicineUniversity of BelgradeBelgrade 11000Serbia Department of Abdominal SurgeryMother and Child Health Care Institute of Serbia“Dr.Vukan Cupic”Belgrade 11000Serbia Faculty of MedicineUniversity of BelgradeBelgrade 11000Serbia
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2024年第30卷第31期
页 面：3654-3667页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：B7 homolog 3 Pancreatic cancer Prognosis Signaling pathways Immunotherapy
摘 要：Despite advances in cancer treatment,pancreatic cancer(PC)remains a disease with high mortality rates and poor survival *** B7 homolog 3(B7-H3)checkpoint molecule is overexpressed among many malignant tumors,including PC,with low or absent expression in healthy *** modulating various immunological and nonimmunological molecular mechanisms,B7-H3 may influence the progression of ***,the impact of B7-H3 on the survival of patients with PC remains a subject of ***,most available scientific data recognize this molecule as a suppressive factor to antitumor immunity in ***,it has been demonstrated that B7-H3 stimulates the migration,invasion,and metastasis of PC cells,and enhances resistance to *** preclinical models of PC,B7-H3-targeting monoclonal antibodies have exerted profound antitumor effects by increasing natural killer cell-mediated antibodydependent cellular cytotoxicity and delivering radioisotopes and cytotoxic drugs to the tumor ***,PC treatment with B7-H3-targeting antibody-drug conjugates and chimeric antigen receptor T cells is being tested in clinical *** review provides a comprehensive analysis of all PC-related studies in the context of B7-H3 and points to deficiencies in the current data that should be overcome by future research.
维普期刊数据库